骨标志物与维持性血液透析患者冠状动脉钙化的关系探讨被引量：1

The relationship between bone markers and coronary artery calcification in patients on maintenance hemodialysis

在线阅读下载PDF

导出

摘要目的探讨骨标志物与维持性血液透析(maintenance hemodialysis,MHD)患者冠状动脉钙化(coronary artery calcification,CAC)的关系,探讨骨标志物的可能影响因素。方法选取温州市人民医院维持性血液透析患者88例,根据冠状动脉钙化积分分钙化组(n=59)和非钙化组(n=29)。收集患者基本资料和生化指标,炎症指标血清淀粉样蛋白A(serum amyloid A protein,SAA)、高敏C反应蛋白(hs-CRP)和白细胞介素-6(interleukin-6, IL-6),检测骨标志物碱性磷酸酶(ALP)、N端-骨钙素(osteocalcin, N-MID)、β-异构C-端肽(type 1 collagen cross-linking β-C terminal peptide,β-CTX)和Ⅰ型原胶原N-端前肽(procollagen type 1 N-terminal propeptide,PINP)。比较2组数据,做骨标志物的相关性分析及冠状动脉钙化危险因素分析。结果 (1)钙化组骨标志物较非钙化组升高[N-MID(t=2.182,P=0.034)、β-CTX(t=2.912,P=0.005)、ALP(t=2.480,P=0.017)],提示钙化组存在高转化骨病。(2)PINP与炎症指标hs-CRP(r=0.438,P=0.001)、IL-6(r=0.357,P=0.028)、SAA(r=0.298,P=0.038)呈正相关;甲状旁腺激素(PTH)与β-CTX(r=0.588,P<0.001)、N-MID(r=0.463,P=0.001)、PINP(r=0.369,P=0.007)、PINP/β-CTX(r=0.364,P=0.009)呈正相关;β2微球蛋白(β2-microglobulin,β2-MG)与N-MID(r=0.389,P=0.005)、PINP(r=0.360,P<0.010)、PINP/β-CTX(r=0.383,P=0.006)呈正相关。LHR(low-/high-density lipoprotein ratio,低密度脂蛋白/高密度脂蛋白比值)与β-CTX(r=0.340,P=0.010)呈正相关。(3)二元Logistic回归分析提示:β-CTX是冠状动脉钙化的独立危险因素(OR=3.43,95%CI:1.51~7.78,P=0.003)。结论骨标志物参与血液透析患者冠状动脉钙化的发生,其中β-CTX可作为独立预测因子。炎症因子、PTH、LHR及β2-MG与骨标志物之间存在相关性,可能共同参与影响血液透析患者骨代谢继而影响冠状动脉钙化。 Objective To investigate the relationship between bone markers and coronary artery calcification(CAC) in patients on maintenance hemodialysis(MHD), and to explore the influencing factors for bone markers in these patients. Methods A total of 88 MHD patients treated in Wenzhou People’s Hospital were recruited. They were divided into CAC group(n=59) and non-CAC group(n=29) based on the CAC score. General clinical data, biochemical results including the inflammation indicators of serum amyloid A protein(SAA), high-sensitivity C-reactive protein(hs-CRP) and interleukin-6(IL-6), and the bone markers of alkaline phosphatase(ALP), N-terminal osteocalcin(N-MID), type 1 collagen cross-linking β-C terminal peptide(β-CTX) and procollagen type 1 N-terminal propeptide(PINP) were recorded. These biochemical parameters were compared between the two groups to evaluate the relationship between bone markers and CAC and the risk factors for CAC. Results(1) The bone markers were higher in CAC group than in non-CAC group [NMID: 174.34±88.44 vs. 120.59±76.32, t=2.182, P=0.034;β-CTX: 2.58±0.99 vs. 1.74±1.0, t=2.912, P=0.005;ALP: 95(59.0~489.00) vs. 83.5(47.0~129.0), t=2.480, P=0.017], suggesting the presence of higher turnover osteopathy in CAC group.(2)Correlation analyses found that PINP was positively correlated with the inflammation indicators of hs-CRP(r=0.438, P=0.001), IL-6(r=0.357, P=0.028) and SAA(r=0.298, P=0.038);parathyroid hormone(PTH) was positively correlated with β-CTX(r=0.588, P=0.000), N-MID(r=0.463, P=0.001),PINP(r=0.369, P=0.007), and PINP/β-CTX(r=0.364, P=0.009);β2-microglobulin(β2-MG) was positively correlated with N-MID(r=0.389, P=0.005), PINP(r=0.360, P<0.010) and PINP/β-CTX(r=0.383, P=0.006);and low-/high-density lipoprotein ratio(LHR) was positively correlated with β-CTX(r=0.340, P=0.010).(3)Binary logistic regression demonstrated that β-CTX was an independent risk factor for CAC(OR=3.433,95% CI: 1.51~7.78, P=0.003). Conclusion Bone markers are implicated in the pathogenesis of CAC. The bone marker of β-CTX can be used as an independent factor for the prediction of CAC. Bone markers are correlated with inflammatory factors, PTH, LHR and β2-MG, and they may collectively participate in the formation of CAC through affecting bone metabolism in MHD patients.

作者周丽娜董芍芍章圣泽王牡丹朱源黄文 ZHOU Li-na;DONG Shao-shao;ZHANG Sheng-ze;WANG Mu-dan;ZHU Yuan;HUANG Wen(Department of Nephrology,The Third Affiliated Hospital of Shanghai University and Wenzhou People's Hospital,Wenzhou 325000,China;Department of Nephrology,The Second Affiliated Hospital of Wenzhou Medical University and Yuying Children’s Hospital,Wenzhou 325000,China)

机构地区温州市人民医院上海大学附属第三医院肾内科温州医科大学附属第二医院、育英儿童医院肾内科

出处《中国血液净化》 CSCD 2023年第2期105-109,共5页 Chinese Journal of Blood Purification

基金温州市科研项目(Y20210878)。

关键词骨标志物 β-异构C-端肽维持性血液透析冠状动脉钙化 Bone marker Type 1 collagen cross-linkingβ-C terminal peptide Maintenance hemodialysis Coronary artery calcification

分类号 R459.5 [医药卫生—治疗学]

作者简介通讯作者:周丽娜,325000,温州,温州市人民医院上海大学附属第三医院肾内科,Email:532754991@qq.com。

引文网络
相关文献

参考文献2

1黄斌,宁珂,陈超,叶山东.绝经后2型糖尿病患者LDL/HDL比值与骨强度以及骨折风险的相关性研究[J].中国骨质疏松杂志,2020,26(2):181-185. 被引量：8
2王喆,魏芳,于海波,王立华,陈海燕,毕学青,孙桂江,张瑞宁,姜埃利.骨硬化蛋白与维持性血液透析患者冠状动脉钙化的关系[J].中华肾脏病杂志,2016,32(1):24-29. 被引量：7

二级参考文献27

1Noordzij M, Cranenburg EM, Engelsman LF, et al. Progression of aortic calcification is associated with disorders of mineral metabolism and mortality in chronic dialysis patients[J]. Nephrol Dial Transplant, 2011, 26(5): 1662-1669. DOI: 10. 1093/ndt/gfq582.
2Karohl C, D'Marco Gasc6n L, Raggi P. Noninvasive imaging for assessment of calcification in chronic kidney disease[J]. Nat Rev Nephrol, 2011, 7(10): 567- 577. DOI: 10.1038/nmeph. 2011.110.
3Chen NX, Moe SM. Vascular calcification: pathophysiology and risk factors[J]. Curr Hypertens Rep, 2012, 14(3): 228-237. DOI: 10.1007/s11906-012-0265-8.
4Agatston AS, Janowitz WR, Hildner FJ, et al. Quantification of coronary artery calcium using ultrafast computed tomography [J]. J Am Coil Cardiol, 1990, 15(4): 827-832.
5Bashir A, Moody WE, Edwards NC, et al. Coronary artery calcium assessment in CKD: utility in cardiovascular disease risk assessment and treatment?[J]. Am J Kidney Dis, 2015, 65 (6): 937-948. DOI: 10.1053/j.ajkd.2015.01.012.
6Shimoyama Y, Tsuruta Y, Niwa T. Coronary artery calcification score is associated with mortality in Japanese hemodialysis patients[J]. J Ren Nutr, 2012, 22(1): 139-142. DOI: 10.1053/j. jrn.2011.10.024.
7Gonqalves FL, Elias RM, dos Reis LM, et al. Serum sclerostin is an independent predictor of mortality in hemodialysis patients[J]. BMC Nephrol, 2014, 15:190-196. DOI: 10.1186/ 1471-2369-15-190.
8Drechsler C, Evenepoel P, Vervloet MG, et al. High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study[J]. Nephrol Dial Transplant, 2015, 30(2): 288 -293. DOI: 10.1093/ndt/gfu301.
9Silverman SL. Sclerostin[J]. J Osteoporos, 2010, 2010:941419. DOI: 10.4061/2010/941419.
10Zhu D, Mackenzie NC, Millan JL, et al. The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells[J]. PLoS One, 2011, 6(5): e19595. DOI: 10.1371/journal.pone.0019595.